Accueil   Diary - News   All news Elsalys Biotech expands its team

Elsalys Biotech expands its team

 Elsalys logo_vertical_CMJNLyon (France), 30 January 2017, ElsaLys Biotech, a fast-growing biotechnology company that designs and develops « best-in-disease » therapeutic antibodies that target tumors and their immune and/or vascular microenvironment, today announces new appointments in its top management team, now complete to support the development of its candidates and its future operations.

 

 

Catherine Mathis, Liliane Bronstein and David Liens, join ElsaLys Biotech as Chief Operating Officer, Vice President Finance and Chief Medical Officer, respectively. Catherine Mathis, PharmD, Chief Operating Officer, has over 25 years’ experience in clinical research and regulatory affairs in the pharmaceutical and biotech industries, particularly in the fields of immunology and oncology.

 

 

Liliane Bronstein, MSG, Vice President Finance, brings to ElsaLys Biotech solid experience in executive management and over 20 years’ financial experience within high growth innovative companies. Finally, David Liens, MD, Chief Medical Officer, brings more than 20 years’ experience in the field of drug development and medical affairs in large pharmaceutical groups and biotech growth companies.

 

 

Read the press realese

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree